Pseudarthrosis Treatment Market

Pseudarthrosis Treatment Market Outlook (2024 to 2034)

The global pseudarthrosis treatment market is estimated to reach a value of US$ 879.4 million in 2024 and thereafter climb to a size of US$ 1.37 billion by 2034, expanding at a CAGR of 4.6% over the next ten years.

Pseudoarthrosis or bone non-union is caused by improper bone fusion after trauma or surgery. Symptoms include discomfort, stiff joints, and decreased range of motion. A range of therapeutic approaches, such as medication therapy, electrical stimulation devices, bone grafting, and surgery, are being applied to treat this condition.

Spinal fusion surgery is occasionally performed by surgeons to address issues with the vertebrae, the bones that make up the spine. It entails uniting the vertebrae into a single, solid bone, which helps with scoliosis, fracture repair, and stability. The condition is known as pseudoarthrosis when the bones are unable to fuse.

The rising number of pseudarthrosis cases, particularly due to factors such as high-impact trauma injuries, osteoporosis, and other bone-related conditions, is driving the demand for effective treatment options. As more individuals suffer from bone non-union, the need for specialized treatment solutions continues to grow globally.

The incidence of pseudarthrosis cases in South Asia & Pacific and North American regions is increasing and it is becoming common among adults aged from 30 to 60 years. Due to this, both regions account for a significant global market share of pseudarthrosis treatment.

Key Market Growth Drivers

• Increasing research and developments of advanced medical devices to treat complex conditions and continuous improvements in biocompatible materials which are particularly designed for healing and fusion purposes are contributing to pseudarthrosis treatment market growth.
• Bone non-union is an extremely complex situation that is still difficult to treat, and this is pushing key players to innovate new methods for better treatment procedures. However, improvements such as bone grafting methods are improving treatment outcomes for pseudarthrosis.
• To increase the fracture healing process or fast recovery after pseudarthrosis surgery, demand for bone growth stimulators is growing.
• Medical professionals widely use bone growth stimulators such as pulsed electromagnetic field devices, capacitive coupling devices, and combined magnetic field devices to gain better results in pseudarthrosis treatment.
• In most cases, pseudarthrosis treatment is becoming extremely expensive for patients depending on the condition. Favorable government reimbursement policies in various countries are contributing to pseudarthrosis treatment market size expansion.

Report Attribute	Detail
Pseudarthrosis Treatment Market Size (2024E)	US$ 879.4 Million
Forecasted Market Value (2034F)	US$ 1.37 Billion
Global Market Growth Rate (2024 to 2034)	4.6% CAGR
North America Market Share (2024E)	45.3%
Western Europe Market Value (2034F)	US$ 240.7 Million
South Asia & Pacific Market Growth Rate (2024 to 2034)	6.4% CAGR
Bone Growth Stimulators Segment Value (2034F)	US$ 433.4 Million
Adult (30 to 60 Years) Segment Value (2034F)	US$ 989.6 Million
Key Companies Profiled	AbbVie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bioventus; Cipla; Daiichi Sankyo; Eli Lilly; Eurofarma; Fresenius; GlaxoSmithKline; Grunenthal; Hikma Pharmaceuticals; Johnson & Johnson; Julphar; Medtronic; Novartis; NuVasive; Orthofix; Pharco Pharmaceuticals; Roche; Sanofi; Stryker; Sun Pharma; Tabuk Pharmaceuticals; Takeda; Teva Pharmaceuticals; UCB; Zimmer Biomet.

Why is Demand for Pseudarthrosis Treatment Increasing Worldwide?

“Treatment Complexity Decreasing with Use of Growth Stimulators, Antibiotics, and Biologics”

Advancements in biologics, bone growth stimulators, antibiotics, stem cell therapy, and other treatments are one of the key pseudarthrosis treatment market trends. When synthetic grafts and biologics are used in advanced bone grafting techniques, they help bones to heal and integrate better. As a result of these improvements, pseudarthrosis treatments are becoming safer and more efficient hence more patients are embracing them and the market continues to expand.

Demand for treatments that work best gets driven heavily by pseudarthrosis escalating at the tip of the iceberg, with much of its incidents resulting from high-impact traumas, osteoporosis, and other bone disorders. As a result of osteopenia and similar conditions, bones fail to grow together forming non-unions at an increased rate that require specialized interventions when fractures do not heal appropriately.

Increasing number of patients affected by this crippling ailment is increasing, this therefore demands the use of more advanced drugs to tackle the problems of pseudarthrosis treatment.

What is the Primary Concern for Market Players?

“High Costs Associated with Complex Pseudarthrosis Treatment”

In some cases, pseudarthrosis becomes extremely complex and time-consuming which leads to an increase in the expenses of treatment. Patients who live in a country with poor health care funding or do not have enough insurance coverage find these costs excessive. This results in high charges associated with treating pseudoarthrosis using complex surgical methods such as bone grafts or some advanced medical devices hence preventing many from accessing this treatment.

Patients with this condition have to wait for longer periods or receive care that is not up to standard because there are no good ways of treating it. Similarly, such expenditure prevents the market as a whole from expanding while at the same time making it hard for people to embrace alternative Medicare measures.

Country-wise Insights

As per Fact.MR’s projection, North America is poised to lead with 45.3% of the pseudarthrosis treatment market share in 2024 and is further projected to occupy 46.1% by 2034. Continuous innovation in the fields of healthcare devices and surgical techniques is the primary reason behind this position. Western

Demand for pseudarthrosis treatment in Europe is forecasted to rise at a 3.2% CAGR from 2024 to 2034. Even though the South Asia & Pacific region is poised to hold only 7.3% market share, it is projected to provide lucrative opportunities for prominent players as demand for pseudarthrosis treatment is forecasted to increase at a 6.4% CAGR through 2034.

What is the Market Scenario for Pseudarthrosis Treatment in the United States?

“Capacity to Adapt and Develop Advanced Treatment Devices”

Attribute	United States
Market Value (2024E)	US$ 349.1 Million
Growth Rate (2024 to 2034)	4.5% CAGR
Projected Value (2034F)	US$ 541.9 Million

In the North American region, the United States is projected to hold 87.5% revenue share in 2024. The United States comes under countries with high healthcare spenders per capita in the world. The country is also well-known in the world for its huge investments in advanced medical treatments which also include pseudarthrosis. This financial capacity of the United States to develop as well as adapt new healthcare technologies is decreasing the complexity and improving outcomes of pseudarthrosis treatment which is ending up attracting patients from several countries.

Why is Need for Pseudarthrosis Treatment Growing at a Fast Rate in India?

“Government Policies Aimed at Improving Access to Pseudarthrosis Treatment”

Attribute	India
Market Value (2024E)	US$ 34.1 Million
Growth Rate (2024 to 2034)	7.8% CAGR
Projected Value (2034F)	US$ 72.6 Million

In some cases, pseudarthrosis treatments are extremely difficult or require a lot of time to recover, which increases the cost for patients. The government in India provides various types of policies such as the Ayushman Bharat policy and state health schemes, so people in the country can get treatment at low cost. With the Ayushman Bharat scheme people with low budgets can easily access pseudarthrosis treatments.

Due to these schemes, people in the country have started to take the required treatment without avoiding any diseases because of worry about finances as well as increasing accessibility coverage and diminishing financial barriers.

Category-wise Insights

By age group, the market is segmented into children, adults, and the elderly. Adults aged between 30 and 60 years are poised to account for a 71.4% revenue share in 2024. Pseudarthrosis mostly results from high-impact injuries sustained by adults, particularly those involved in physically demanding jobs, sports, and other activities.

Which Type of Treatment is Widely Preferred for Pseudarthrosis?

“Preference for Bone Growth Stimulators among Healthcare Providers and Patients”

Attribute	Bone Growth Stimulators
Segment Value (2024E)	US$ 258.9 Million
Growth Rate (2024 to 2034)	5.3% CAGR
Projected Value (2034F)	US$ 433.4 Million

Since bone growth stimulators are less invasive and more effective, they are usually considered most suitable for treating pseudarthrosis. Electrical stimulus or ultrasound therapy is employed in these gadgets to prompt cell function and create growth factors that facilitate the healing process in bones.

Cases that fail to respond to traditional methods such as casting or operation are ones where bone growth stimulators are greatly relied on. By applying them externally, the risks that come with invasive operations are minimized. Moreover, they help the patients keep some level of movement while being treated.

Why Do Hospitals Account for a Significant Market Share?

“Availability of Advanced Tools and Specialized Rooms for Treatment”

Attribute	Hospitals
Segment Value (2024E)	US$ 389.1 Million
Growth Rate (2024 to 2034)	4.2% CAGR
Projected Value (2034F)	US$ 589.7 Million

Patients with pseudarthrosis problems mostly choose hospitals. Most of the hospitals have the advanced equipment and specialized surgery rooms needed to carry out difficult treatments such as spinal fusion and bone grafting, which are needed to cure pseudoarthrosis.

Hospitals also have multidisciplinary teams of specialists-orthopedic surgeons, radiologists, and physical therapists all work together to give the patients comprehensive treatment until complete recovery as a result, such hospitals are most commonly chosen by patients with complex cases of nonunion.

Competitive Landscape

Key players in the pseudarthrosis treatment industry are trying to minimize the complexity of the related procedures. Ongoing advancements in gadgets and innovation in biologics, antibiotics, stem cell therapy, bone growth stimulators, and many others helping to increase the pseudarthrosis treatment outcomes.

• In December 2023, a leading worldwide provider of spine and orthopedic treatments, Orthofix Medical Inc., announced the release of fresh findings from a prospective, multicenter study examining the use of pulsed electromagnetic field stimulation (PEMF) as a post-operative treatment for lumbar spinal fusion procedures in individuals at risk of pseudoarthrosis. Despite having risk factors for pseudoarthrosis, patients treated with the SpinalStim bone growth treatment device showed a high incidence of successful fusion with notable benefits in pain, function, and quality of life, as reported in the International Journal of Spine Surgery1.
• In December 2022, the United States Food and Drug Administration (FDA) approved Providence Medical Technology's CAVUX facet fixation system (FFS) for a new use: patients who need autogenous or allogenic bone graft revision for anterior pseudarthrosis at one level, from C3 to C7. The FFS is a unique integrated cage and screw device that is placed in both facet joints to stabilize the joints until fusion takes place.

Fact.MR provides detailed information about the price points of prominent players in the pseudarthrosis treatment market positioned across the world, sales growth, production capacity, and speculative technological expansion, in this new market report.

Segmentation of Pseudarthrosis Treatment Market Research

• By Treatment Type :

  • Biologics
  • NSAIDs
  • Opioid & Non-opioid Analgesics
  • Corticosteroids
  • Bone Growth Stimulators
  • Antibiotics
  • Stem Cell Therapy
  • Orthobiologics

• By Age Group :

  • Children (0 to 18 years)
  • Adults (30 to 60 years)
  • Elderly (60+ years)

• By Mode of Purchase :

  • Rx
  • OTC

• By End User :

  • Hospitals
  • Specialty Clinics
  • Outpatient Surgical Centers
  • Home Care Settings

• By Region :

  • North America
  • Western Europe
  • Eastern Europe
  • Latin America
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa